middle.news
Actinogen Secures EMA Guidance Aligning with FDA for Xanamem Alzheimer’s Pathway
9:51am on Thursday 28th of May, 2026 AEST
•
Healthcare
Read Story
Actinogen Secures EMA Guidance Aligning with FDA for Xanamem Alzheimer’s Pathway
9:51am on Thursday 28th of May, 2026 AEST
Key Points
EMA agrees on regulatory starting materials for Xanamem
One additional pivotal Phase 3 trial planned with broader patient inclusion
EMA and FDA guidance align on safety database and ancillary studies
Final XanaMIA trial results expected November 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE